XML 33 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Collaboration and Other Agreements - Incyte Corporation (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
Oct. 31, 2017
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2017
Jun. 30, 2020
Jun. 30, 2019
Sep. 30, 2019
Collaboration And Other Agreements [Line Items]              
Revenues   $ 20,257,000 $ 10,593,000   $ 33,939,000 $ 20,255,000  
Incyte Corporation | Incyte MGA012 Agreement              
Collaboration And Other Agreements [Line Items]              
Non-refundable upfront payment       $ 150,000,000.0      
Potential development and regulatory milestone payments under agreement $ 420,000,000.0            
Potential commercial milestone payments under agreement 330,000,000.0            
Development and regulatory milestones recognized             $ 15,000,000.0
Collaborative agreement transaction price 154,000,000.0            
Variable consideration recognized $ 4,000,000.0            
Maximum | Incyte Corporation | Incyte MGA012 Agreement              
Collaboration And Other Agreements [Line Items]              
Potential proceeds from royalties (percent) 24.00%            
Minimum | Incyte Corporation | Incyte MGA012 Agreement              
Collaboration And Other Agreements [Line Items]              
Potential proceeds from royalties (percent) 15.00%            
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement              
Collaboration And Other Agreements [Line Items]              
Revenues $ 150,000,000.0            
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Clinical activities              
Collaboration And Other Agreements [Line Items]              
Revenues   0 0        
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Services              
Collaboration And Other Agreements [Line Items]              
Revenues   $ 1,500,000 $ 4,200,000   $ 7,400,000 $ 8,200,000